Publications by authors named "Mengchen Lyu"
Article Synopsis
- The study investigates immune checkpoint inhibitor-associated pneumonitis (CIP) in non-small cell lung cancer (NSCLC) patients receiving anti-PD-1 therapy, aiming to identify risk factors and their impact on prognosis.
- Out of 229 patients analyzed, 15.3% experienced CIP, with higher occurrences among males and those with prior smoking or lung disease; elevated CD4 T lymphocytes and AEC were found to be significant predictors of CIP.
- The presence of CIP was linked to improved progression-free survival and better treatment efficacy, highlighting the necessity for early detection and intervention.
Background: The incidence of multiple primary cancers (MPC), especially involving primary lung cancer (PLC) and primary hematologic malignancies (PHM), is rising. This study aims to analyze clinicopathological features, gene abnormalities, and prognostic outcomes in individuals diagnosed with PLC-PHM MPC.
Methods: A retrospective analysis included 89 patients diagnosed with PLC-PHM MPC at the Respiratory or Hematology Departments of Ruijin Hospital from 2003 to 2022 (a total of 842,047 people).
Background: The rechallenge of immune checkpoint inhibitors (ICI) is now an optional strategy for patients who discontinued ICI due to immune-related adverse events (irAEs) or disease progression. However, little data is available for the prognosis and prognostic factors of patients receiving ICI rechallenge treatment in advanced lung cancer patients. Our study aimed to explore the efficacy, prognosis and safety of patients who received anti-programmed cell death-1/programmed cell death ligand 1 (anti-PD-1/PD-L1) inhibitor rechallenge.
View Article and Find Full Text PDF